万赛维是什么？

It is an antiviral drug used to treat patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis, and to prevent CMV infection in high-risk solid organ transplant patients. On August 11, 2010, the U.S. Food and Drug Administration (FDA) approved the increased use of valamciclovir hydrochloride in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

Adult patients: (1) Induction treatment of CMV retinitis: For patients with active CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Prolonged induction therapy may increase the risk of bone marrow toxicity. (2) Maintenance treatment of CMV retinitis: After induction therapy, or for patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once daily. Induction therapy may be repeated in patients with worsening retinitis.

(3) Prevention of CMV infection in transplant patients: ① For kidney transplant patients, the recommended dose is 900 mg (two 450 mg tablets), once a day, starting within 10 days after transplantation until 200 days after transplantation. ②For patients who have received a solid organ transplant other than kidney, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation.

Adverse Reactions: In both clinical trials (n = 370), the most commonly reported adverse events (% of patients) in the treatment group, regardless of severity and whether drug-related, were diarrhea (38%), pyrexia (26%), nausea (25%), neutropenia (24%), and anemia (22%). Most adverse events were mild or moderate. Regardless of severity, the most common events reported by investigators to be related (including possibly unrelated, possibly related, and probably related) to vasevir were neutropenia (21%), anemia (14%), diarrhea (13%), and nausea (9%).